 SOUTH SAN FRANCISCO, Calif., July 29, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET 2:00 p.m. PT to discuss the results and provide a corporate update. 